Dose-Dense Paclitaxel-And Carboplatin-Based Neoadjuvant Chemotherapy Followed By Surgery Or Concurrent Chemoradiotherapy In Cervical Cancer: A Preliminary Analysis

Aim: To assess preliminary results with dosedense neoadjuvant chemotherapy (NACT) prior to surgery or concurrent chemo-radiotherapy (CCRT) in cervical cancer. Patients and Methods: Thirty patients received weekly paclitaxel (80 mg/m(2)) plus carboplatin (AUC2) for 6 cycles followed by radical hysterectomy in 16 (stage Ib(2)-IIb), conisation in one (stage Ib1), and CCRT in 13 (stage Ib(2)-IIb). Median follow-up of survivors was 12 months (range= 3-22). Results: Among the surgically treated patients, clinical overall response rate (RR) was 82.3%, optimal pathological RR was 17.6%, and suboptimal pathological RR with intracervical residual disease was 41.2%. Only one patient relapsed. Among the CCRT treated patients, partial RR after NACT was 76.9% and complete RR after CCRT was 58.3%. However, 42.8% of complete responders recurred. Toxicity was acceptable. Conclusion: Dose-dense NACT seems to achieve promising RRs with manageable toxicity in cervical cancer. Investigation on larger series with longer follow-up is warranted.